List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4712549/publications.pdf Version: 2024-02-01



Μλήσι Βεήσλοι

#	Article	IF	CITATIONS
1	Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Molecular Immunology, 2012, 50, 35-41.	2.2	97
2	Single-Domain Antibodies or Nanobodies: A Class of Next-Generation Antibodies. International Reviews of Immunology, 2018, 37, 316-322.	3.3	74
3	Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New Biotechnology, 2013, 30, 205-209.	4.4	68
4	Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody. Molecular Immunology, 2015, 65, 58-67.	2.2	60
5	Oral DNA vaccines based on CS-TPP nanoparticles and alginate microparticles confer high protection against infectious pancreatic necrosis virus (IPNV) infection in trout. Developmental and Comparative Immunology, 2017, 74, 178-189.	2.3	57
6	Albumin nanoparticles as nanocarriers for drug delivery: Focusing on antibody and nanobody delivery and albumin-based drugs. Journal of Drug Delivery Science and Technology, 2020, 55, 101471.	3.0	52
7	T cell engineered with a novel nanobodyâ€based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. IUBMB Life, 2019, 71, 1259-1267.	3.4	45
8	The first report on transcriptome analysis of the venom gland of Iranian scorpion, Hemiscorpius lepturus. Toxicon, 2017, 125, 123-130.	1.6	37
9	VP2 (PTA motif) encoding DNA vaccine confers protection against lethal challenge with infectious pancreatic necrosis virus (IPNV) in trout. Molecular Immunology, 2018, 94, 61-67.	2.2	35
10	An overview on application of phage display technique in immunological studies. Asian Pacific Journal of Tropical Biomedicine, 2017, 7, 599-602.	1.2	34
11	Design and characterization of short hybrid antimicrobial peptides from <scp>pEM</scp> â€2, mastoparanâ€ <scp>VT</scp> 1, and mastoparanâ€8. Chemical Biology and Drug Design, 2017, 89, 327-338.	3.2	33
12	Nanobodies as novel therapeutic agents in envenomation. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2955-2965.	2.4	30
13	Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2016, 35, 167-171.	1.6	28
14	Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3). Iranian Journal of Basic Medical Sciences, 2016, 19, 1201-1208.	1.0	28
15	A camelid antibody candidate for development of a therapeutic agent against <i>Hemiscorpius lepturus</i> envenomation. FASEB Journal, 2014, 28, 4004-4014.	O.5	26
16	Development of a monoâ€specific antiâ€VEGF bivalent nanobody with extended plasma halfâ€life for treatment of pathologic neovascularization. Drug Testing and Analysis, 2020, 12, 92-100.	2.6	25
17	A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1233-1239.	5.2	25
18	Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization. Cancer Gene Therapy, 2017, 24, 33-37.	4.6	24

#	Article	IF	CITATIONS
19	Expression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor. Advanced Pharmaceutical Bulletin, 2014, 4, 323-8.	1.4	24
20	Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis. Journal of Medical Microbiology, 2006, 55, 1657-1659.	1.8	23
21	Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis. Molecular Immunology, 2016, 78, 183-192.	2.2	22
22	Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NSO host cell. Protein Expression and Purification, 2016, 123, 19-25.	1.3	22
23	Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity. Molecular Biotechnology, 2020, 62, 18-30.	2.4	22
24	Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 1402-1414.	2.8	20
25	immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies. Iranian Journal of Basic Medical Sciences, 2017, 20, 489-496.	1.0	19
26	Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34, 201-205.	1.6	18
27	Development of a recombinant camelid specific diabody against the heminecrolysin fraction of <i>Hemiscorpius lepturus</i> scorpion. Toxin Reviews, 2017, 36, 7-11.	3.4	18
28	An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization. Immunopharmacology and Immunotoxicology, 2018, 40, 368-374.	2.4	18
29	Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Molecular Immunology, 2021, 129, 70-77.	2.2	18
30	Development of anti-CD47 single-chain variable fragment targeted magnetic nanoparticles for treatment of human bladder cancer. Nanomedicine, 2017, 12, 597-613.	3.3	17
31	Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature. Molecular Biotechnology, 2016, 58, 738-747.	2.4	16
32	Expression of VGRNb-PE immunotoxin in transplastomic lettuce (Lactuca sativa L.). Plant Molecular Biology, 2018, 97, 103-112.	3.9	16
33	Generation and characterization of an anti-delta like ligand-4 Nanobody to induce non-productive angiogenesis. Analytical Biochemistry, 2018, 544, 34-41.	2.4	16
34	Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its function. Iranian Journal of Basic Medical Sciences, 2018, 21, 260-266.	1.0	16
35	Development of protective agent against Hottentotta saulcyi venom using camelid single-domain antibody. Molecular Immunology, 2015, 68, 412-420.	2.2	15
36	Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. Journal of Immunotoxicology, 2019, 16, 34-42.	1.7	15

#	Article	IF	CITATIONS
37	CharacteristicsÂandÂLethalityÂofÂaÂNovelÂRecombinant DermonecroticÂVenomÂPhospholipaseÂDÂfromÂ HemiscorpiusÂlepturus. Toxins, 2017, 9, 102.	3.4	14
38	Recombinant expression and purification of human placental growth factor 1 and specific camel heavy chain polyclonal antibody preparation. Saudi Journal of Biological Sciences, 2014, 21, 35-39.	3.8	12
39	Identification of the immunogenic epitopes of the whole venom component of the Hemiscorpius lepturus scorpion using the phage display peptide library. Toxicon, 2016, 124, 83-93.	1.6	12
40	Camelid antivenom development and potential inÂvivo neutralization of Hottentotta saulcyi scorpion venom. Toxicon, 2016, 113, 70-75.	1.6	12
41	Development and characterization of a camelid singleâ€domain antibody directed to human CD22 biomarker. Biotechnology and Applied Biochemistry, 2018, 65, 718-725.	3.1	12
42	Genotoxicity assessment of antiepileptic drugs (AEDs) in human embryonic stem cells. Epilepsy Research, 2019, 158, 106232.	1.6	12
43	Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129974.	2.4	12
44	Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors. Journal of Drug Targeting, 2020, 28, 379-385.	4.4	11
45	Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis. Molecular Immunology, 2020, 128, 56-63.	2.2	11
46	Development of a novel engineered antibody targeting human CD123. Analytical Biochemistry, 2016, 511, 27-30.	2.4	10
47	Development of a human scFv antibody targeting the lethal Iranian cobra (Naja oxiana) snake venom. Toxicon, 2019, 171, 78-85.	1.6	10
48	Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae. Biotechnology Reports (Amsterdam, Netherlands), 2019, 24, e00385.	4.4	10
49	Development and characterization of human single chain antibody against Iranian Macrovipera lebetina snake venom. Toxicon, 2021, 197, 106-113.	1.6	10
50	Human IL-2RÉ' subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach. PLoS ONE, 2022, 17, e0264353.	2.5	9
51	Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: Vascular endothelial growth factor receptor 2. Advanced Biomedical Research, 2012, 1, 34.	0.5	8
52	Cloning, Expression and One-Step Purification of a Novel IP-10-(anti-HER2 scFv) Fusion Protein in Escherichia coli. International Journal of Peptide Research and Therapeutics, 2021, 27, 433-446.	1.9	8
53	Antigenic assessment of a recombinant human CD90 protein expressed in prokaryotic expression system. Protein Expression and Purification, 2015, 116, 139-143.	1.3	7
54	Recombinant expression and purification of functional vascular endothelial growth factor-121 in the baculovirus expression system. Asian Pacific Journal of Tropical Medicine, 2016, 9, 1195-1199.	0.8	7

#	Article	IF	CITATIONS
55	Developing recombinant phospholipase D1 (rPLD1) toxoid from Iranian Hemiscorpius lepturus scorpion and its protective effects in BALB/c mice. Toxicon, 2018, 152, 30-36.	1.6	7
56	Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis. CNS and Neurological Disorders - Drug Targets, 2019, 18, 141-148.	1.4	7
57	Modified PO–PO hybrid method for scattering of 2D ship model on the rough sea surface. IET Microwaves, Antennas and Propagation, 2019, 13, 156-162.	1.4	6
58	Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies. Cancer Chemotherapy and Pharmacology, 2022, 89, 165-172.	2.3	6
59	Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin. Immunopharmacology and Immunotoxicology, 2021, 43, 230-238.	2.4	5
60	In Vitro Evaluation of Vegf-Pseudomonas Exotoxin: A Conjugated on Tumor Cells. Advanced Biomedical Research, 2017, 6, 144.	0.5	5
61	A Model to Study the Phenotypic Changes of Insect Cell Transfection by Copepod Super Green Fluorescent Protein (cop-GFP) in Baculovirus Expression System. Iranian Biomedical Journal, 2016, 20, 182-6.	0.7	5
62	Electromagnetic scattering from a pec target over a random rough sea surface using hybrid KA-PO-PTD method. , 2017, , .		4
63	Transient expression of anti-VEFGR2 nanobody in Nicotiana tabacum and N. benthamiana. 3 Biotech, 2018, 8, 484.	2.2	4
64	combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies. Iranian Journal of Basic Medical Sciences, 2020, 23, 1335-1339.	1.0	4
65	Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigen. Iranian Biomedical Journal, 2012, 16, 121-6.	0.7	4
66	Immunological evaluation of predicted linear Bâ€ɛell epitopes of human CD20 antigen. Biotechnology and Applied Biochemistry, 2012, 59, 186-192.	3.1	3
67	Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 310-316.	1.0	3
68	Evaluation of Laboratory Application of Camelid Sera Containing Heavy-Chain Polyclonal Antibody Against Recombinant Cytotoxic T-Lymphocyte-Associated Protein-4. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2019, 38, 235-241.	1.6	3
69	Recombinant Expression of Zinc Transporter SLC39A6 and Its Functional Antibody Production. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2019, 38, 70-74.	1.6	3
70	Production of Novel Camelid Anti-CXCL10 Specific Polyclonal Antibodies and Evaluation of Their Bioreactivity. International Journal of Peptide Research and Therapeutics, 2019, 25, 535-540.	1.9	3
71	Optimization of Anti-CXCL10 Nanobody Expression Using Response Surface Methodology and Evaluation of its Anti-metastatic Effect on Breast Cancer cells. International Journal of Peptide Research and Therapeutics, 2020, 26, 1399-1407.	1.9	3
72	Designing and Development of a Tandem Bivalent Nanobody against VEGF165. Avicenna Journal of Medical Biotechnology, 2021, 13, 58-64.	0.3	3

#	Article	IF	CITATIONS
73	<i>In Vivo</i> Tumor Therapy with Novel Immunotoxin Containing Programmed Cell Death Protein-1 and Diphtheria Toxin. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 113-117.	1.6	3
74	Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3. Iranian Journal of Biotechnology, 2017, 15, 166-171.	0.3	3
75	Expression and purification of truncated diphtheria toxin, DT386, in Escherichia coli: An attempt for production of a new vaccine against diphtheria. Research in Pharmaceutical Sciences, 2016, 11, 428.	1.8	3
76	Efficacy and antitumor activity of a mutant type of interleukin 2. Scientific Reports, 2022, 12, 5376.	3.3	3
77	Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line. Molecular Biotechnology, 2022, 64, 1218-1226.	2.4	3
78	Camel Heavy Chain Polyclonal Antibody Raised Against Recombinant Murine Placental Growth Factor Expressed in Escherichia coli. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34, 126-130.	1.6	2
79	Electromagnetic scattering from a PEC target buried beneath a rough surface using KA-PO method. , 2016, , .		2
80	Datasets of a novel bivalent single chain antibody constructed by overlapping oligonucleotide annealing method targeting human CD123. Data in Brief, 2016, 8, 1137-1143.	1.0	2
81	Functional Study of a Camelid Single Domain Anti-CD22 Antibody. International Journal of Peptide Research and Therapeutics, 2020, 26, 633-639.	1.9	2
82	Phylogenetic analysis of metalloprotease from transcriptome of venom gland of Hemiscorpius lepturus. Archives of Biotechnology and Biomedicine, 2019, 3, 006-010.	0.2	2
83	Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates. International Immunopharmacology, 2022, 105, 108585.	3.8	2
84	Apoplastic Production of Recombinant AntiVEGF Protein Using Plant-Virus Transient Expression Vector. Molecular Biotechnology, 2022, , 1.	2.4	2
85	Anti-VEGFR2 nanobody expression in lettuce using an infectious Turnip mosaic virus vector. Journal of Plant Biochemistry and Biotechnology, 2017, 27, 167.	1.7	1
86	Enhanced expression and purification of anti-VEGF nanobody in cucurbit plants. Journal of Plant Biochemistry and Biotechnology, 2019, 28, 263-270.	1.7	1
87	Linear mimotope analysis of Iranian cobra (Naja oxiana) snake venom using peptide displayed phage library. Toxin Reviews, 2019, 38, 106-114.	3.4	1
88	Complete neutralization of the lethality of Hemiscorpius lepturus crude venom by a novel anti-recombinant phospholipase D1 IgGs. Toxicon, 2020, 183, 36-43.	1.6	1
89	Design and Analysis of a Wideband CPW-Fed Circularly-Polarized Antenna. , 2020, , .		1
90	Cell-specific targeting by engineered M13 bacteriophage expressing VEGFR2 nanobody. Iranian Journal of Basic Medical Sciences, 2018, 21, 884-888.	1.0	1

#	Article	IF	CITATIONS
91	Development of a novel in vitro assay for the evaluation of integron DNA integrase activity. Biotechnology and Biotechnological Equipment, 2016, 30, 585-591.	1.3	0
92	A novel toxoid phospholipase D1 from Iranian Hemiscorpius lepturus scorpion and immunogenicity studies in BALB/c mice. Toxicon, 2019, 159, S22-S23.	1.6	0
93	Evaluation of Sensitivity of Molecular Methods for Detection of Rifampin-Resistant Strains Amongst Drug-resistant Mycobacterium tuberculosis Isolates. Archives of Pediatric Infectious Diseases, 2016, inpress, .	0.3	0
94	Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines. Iranian Journal of Allergy, Asthma and Immunology, 2019, 18, 679-687.	0.4	0
95	A comparative study on the equine and camelid antivenoms upon cardiovascular changes induced with venom in rats. Iranian Journal of Basic Medical Sciences, 2019, 22, 1440-1444.	1.0	0
96	Expressing of Recombinant VEGFR2-specific Nanobody in Baculovirus Expression System. Iranian Journal of Biotechnology, 2021, 19, e2783.	0.3	0
97	Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4) Iranian Journal of Basic Medical Sciences, 2021, 24, 1264-1271.	1.0	0
98	Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein Iranian Journal of Basic Medical Sciences, 2021, 24, 1726-1733.	1.0	0